Pacific Biosciences of California, Inc. PACB

NKTR, QSI, and PACB are drawing attention from options bears

Shares of genomics company Pacific Biosciences of California (NASDAQ:PACB) jumped 29.7% in the afternoon session after EpiSign announced the launch of EpiSign METRIC 5-base, enabling laboratories to analyze DNA methylation data on the company's HiFi sequencing platform.

Check out the companies making headlines yesterday:

Shares of genomics company Pacific Biosciences of California (NASDAQ:PACB) jumped 5.8% in the afternoon session after genomics provider Sampled announced a five-year contract worth up to $27.1 million from the U.S. Department of Veterans Affairs to support research using PacBio Revio sequencing systems.

Unprofitable companies face headwinds as they struggle to keep operating expenses under control. Some may be investing heavily, but the majority fail to convert spending into sustainable growth.

Stocks trading in the $1-10 range are generally smaller players with less risk than their penny stock counterparts. But that doesn’t mean the underlying businesses are cheap, and we advise caution as many have questionable fundamentals.

Small-cap stocks can be incredibly lucrative investments because their lack of analyst coverage leads to frequent mispricings. However, these businesses (and their stock prices) often stay small because their subscale operations make it harder to expand their competitive moats.

Rapid spending isn’t always a sign of progress. Some cash-burning businesses fail to convert investments into meaningful competitive advantages, leaving them vulnerable.

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at PacBio (NASDAQ:PACB) and the best and worst performers in the life sciences tools & services industry.

MENLO PARK, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that management will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference on Tuesday, September 15, 2026, at 4:50 PM ET in New York, New York. A live webcast of the event can be accessed at the company’s investors page at investor.pacificbiosciences.com. A replay of the webcast will be ava

Shareholders of PacBio would probably like to forget the past six months even happened. The stock dropped 20.5% and now trades at $1.29. This was partly due to its softer quarterly results and may have investors wondering how to approach the situation.